tradingkey.logo

Vor Biopharma Inc

VOR

2.170USD

0.000
Fechamento 08/22, 16:00ETCotações atrasadas em 15 min
272.65MValor de mercado
PerdaP/L TTM

Vor Biopharma Inc

2.170

0.000
Mais detalhes de Vor Biopharma Inc Empresa
Vor Biopharma Inc. is a clinical-stage cell and genome engineering therapy company. The Company is engaged in combining a novel patient engineering approach with targeted therapies to provide solutions for patients suffering from hematological malignancies. Its proprietary platform leverages expertise in hematopoietic stem cell (HSC) biology, genome engineering and targeted therapy development to genetically modify HSCs to remove surface targets expressed by cancer cells. The Company’s lead engineered hematopoietic stem cells (eHSC) product candidate include tremtelectogene empogeditemcel (trem-cel), for the treatment for acute myeloid leukemia (AML) and other blood cancers. It is designed to replace the standard of care in transplant settings for patients suffering from acute myeloid leukemia (AML) and other blood cancers. Its VBP101 is a Phase I/II a multicenter, open-label, first-in-human study of trem-cel in patients with AML.
Informações da empresa
Código da empresaVOR
Nome da EmpresaVor Biopharma Inc
Data de listagemFeb 05, 2021
CEODr. Jean-Paul Kress, M.D.
Número de funcionários159
Tipo de títulosOrdinary Share
Fim do ano fiscalFeb 05
Endereço100 Cambridgepark Drive
CidadeCAMBRIDGE
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal02140
Telefone16176556580
Sitehttps://www.vorbio.com/
Código da empresaVOR
Data de listagemFeb 05, 2021
CEODr. Jean-Paul Kress, M.D.
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Sandesh (Sandy) Mahatme
Mr. Sandesh (Sandy) Mahatme
Chief Financial Officer, Chief Business Officer
Chief Financial Officer, Chief Business Officer
13.88M
--
Dr. Qing Zuraw
Dr. Qing Zuraw
Chief Development Officer
Chief Development Officer
937.08K
--
Mr. Erez Kalir
Mr. Erez Kalir
Independent Director
Independent Director
--
--
Mr. David Charles Lubner, CPA
Mr. David Charles Lubner, CPA
Independent Director
Independent Director
--
--
Dr. Fouad Namouni, M.D.
Dr. Fouad Namouni, M.D.
Independent Director
Independent Director
--
--
Dr. Joshua B. (Josh) Resnick, M.D.
Dr. Joshua B. (Josh) Resnick, M.D.
Independent Director
Independent Director
--
--
Ms. Daniella Beckman, CPA
Ms. Daniella Beckman, CPA
Independent Director
Independent Director
--
--
Dr. Jean-Paul Kress, M.D.
Dr. Jean-Paul Kress, M.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Mr. Dallan Murray
Mr. Dallan Murray
Chief Commercial Officer
Chief Commercial Officer
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Sandesh (Sandy) Mahatme
Mr. Sandesh (Sandy) Mahatme
Chief Financial Officer, Chief Business Officer
Chief Financial Officer, Chief Business Officer
13.88M
--
Dr. Qing Zuraw
Dr. Qing Zuraw
Chief Development Officer
Chief Development Officer
937.08K
--
Mr. Erez Kalir
Mr. Erez Kalir
Independent Director
Independent Director
--
--
Mr. David Charles Lubner, CPA
Mr. David Charles Lubner, CPA
Independent Director
Independent Director
--
--
Dr. Fouad Namouni, M.D.
Dr. Fouad Namouni, M.D.
Independent Director
Independent Director
--
--
Dr. Joshua B. (Josh) Resnick, M.D.
Dr. Joshua B. (Josh) Resnick, M.D.
Independent Director
Independent Director
--
--
Detalhamento da receita
Sem dados
Sem dados
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: ter, 19 de ago
Atualizado em: ter, 19 de ago
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
RA Capital Management, LP
31.30%
Reprogrammed Interchange LLC
30.77%
Mahatme (Sandesh)
10.96%
5AM Ventures
3.49%
Fidelity Management & Research Company LLC
1.59%
Outro
21.90%
Investidores
Investidores
Proporção
RA Capital Management, LP
31.30%
Reprogrammed Interchange LLC
30.77%
Mahatme (Sandesh)
10.96%
5AM Ventures
3.49%
Fidelity Management & Research Company LLC
1.59%
Outro
21.90%
Tipos de investidores
Investidores
Proporção
Venture Capital
35.67%
Corporation
30.77%
Individual Investor
12.08%
Investment Advisor
5.49%
Hedge Fund
0.98%
Research Firm
0.71%
Investment Advisor/Hedge Fund
0.67%
Bank and Trust
0.14%
Outro
13.51%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
165
100.29M
80.27%
+23.22M
2025Q1
174
100.82M
80.73%
+21.38M
2024Q4
172
101.57M
81.78%
+39.14M
2024Q3
175
49.60M
72.03%
-12.93M
2024Q2
174
56.25M
82.04%
-8.25M
2024Q1
168
60.63M
88.57%
-4.75M
2023Q4
163
60.90M
89.54%
-3.77M
2023Q3
164
61.10M
90.20%
-4.10M
2023Q2
166
61.68M
92.10%
-1.24M
2023Q1
168
61.85M
93.27%
-1.28M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
RA Capital Management, LP
39.65M
31.73%
--
--
Jun 25, 2025
Reprogrammed Interchange LLC
38.97M
31.19%
+38.97M
--
Dec 30, 2024
5AM Ventures
6.36M
5.09%
--
--
Mar 31, 2025
Fidelity Management & Research Company LLC
6.34M
5.07%
+5.39K
+0.09%
Mar 31, 2025
The Vanguard Group, Inc.
1.94M
1.55%
-2.60K
-0.13%
Mar 31, 2025
Johnson & Johnson Innovation-JJDC, Inc.
1.07M
0.86%
--
--
Mar 31, 2025
Jane Street Capital, L.L.C.
194.76K
0.16%
+194.76K
--
Mar 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: qua, 6 de ago
Atualizado em: qua, 6 de ago
Nome
Proporção
ProShares UltraPro Russell2000
0%
ProShares Hedge Replication ETF
0%
iShares Russell 2000 ETF
0%
Global X Russell 2000 ETF
0%
iShares Micro-Cap ETF
0%
iShares Russell 2000 Value ETF
0%
Global X Russell 2000 Covered Call ETF
0%
Proshares Ultra Russell 2000
0%
Dimensional US Core Equity 1 ETF
0%
ProShares UltraPro Russell2000
Proporção0%
ProShares Hedge Replication ETF
Proporção0%
iShares Russell 2000 ETF
Proporção0%
Global X Russell 2000 ETF
Proporção0%
iShares Micro-Cap ETF
Proporção0%
iShares Russell 2000 Value ETF
Proporção0%
Global X Russell 2000 Covered Call ETF
Proporção0%
Proshares Ultra Russell 2000
Proporção0%
Dimensional US Core Equity 1 ETF
Proporção0%
Dividendo
Um total de 0.00 USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
KeyAI